NR3C2 and neoplasm: We conclude that anti-CRD4-MR scFv #G11 can prevent tumor-induced macrophage dynamic changes, which provides a proof of principle for the targeting CRD4-MR mannose binding domain as a mean to re-set the innate immune response towards tumor rejection.